Cargando…

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

The CD33/CD3-bispecific T-cell engaging (BiTE) antibody construct, AMG 330, potently lyses CD33+ leukemic cells in vitro. Using specimens from 41 patients with acute myeloid leukemia (AML), we studied the factors that might contribute to clinical response or resistance. For this purpose, thawed aliq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrington, Kimberly H., Gudgeon, Chelsea J., Laszlo, George S., Newhall, Kathryn J., Sinclair, Angus M., Frankel, Stanley R., Kischel, Roman, Chen, Guang, Walter, Roland B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549148/ https://www.ncbi.nlm.nih.gov/pubmed/26305211 http://dx.doi.org/10.1371/journal.pone.0135945

Ejemplares similares

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
por: Laszlo, G S, et al.
Publicado: (2015)

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
por: Jitschin, Regina, et al.
Publicado: (2018)

CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Correction to: CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Immunotherapy using bispecific T cell engager (BiTE(®)) antibodies: preclinical and clinical experience in acute leukemia
por: Subklewe, Marion, et al.
Publicado: (2014)

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
por: Laszlo, George S., et al.
Publicado: (2016)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
por: Kebenko, Maxim, et al.
Publicado: (2018)

FLT3‐ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression
por: Soare, Dan‐Sebastian, et al.
Publicado: (2020)

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
por: Allen, Cecily, et al.
Publicado: (2021)

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE(®) Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
por: Hoffman, Lindsey M., et al.
Publicado: (2014)

Repression of phagocytosis by human CD33 is not conserved with mouse CD33
por: Bhattacherjee, Abhishek, et al.
Publicado: (2019)

S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS
por: Haubner, Sascha, et al.
Publicado: (2023)

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
por: Wu, Jingjing, et al.
Publicado: (2015)

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
por: Rosen, David B., et al.
Publicado: (2013)

Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed Immunotherapy
por: Godwin, Colin D., et al.
Publicado: (2021)

CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML)
por: Jiang, Yongfang, et al.
Publicado: (2017)

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
por: Stanchina, Michele, et al.
Publicado: (2019)

Author Correction: Repression of phagocytosis by human CD33 is not conserved with mouse CD33
por: Bhattacherjee, Abhishek, et al.
Publicado: (2020)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy
por: Cairoli, Roberto, et al.
Publicado: (2023)

A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
por: Brey, Charlotte U., et al.
Publicado: (2018)

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML
por: Perriello, Vincenzo Maria, et al.
Publicado: (2022)

Expression of CD25 fluctuates in the leukemia-initiating cell population of CD25-positive AML
por: Kageyama, Yuki, et al.
Publicado: (2018)

Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway
por: Shen, Ye, et al.
Publicado: (2022)

Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110
por: Deisting, Wibke, et al.
Publicado: (2015)

T-cell responses against CD19(+) pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
por: Feucht, Judith, et al.
Publicado: (2016)

P522: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
por: Huang, Ruihao, et al.
Publicado: (2023)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

Comparison of AMG 416 and cinacalcet in rodent models of uremia
por: Walter, Sarah, et al.
Publicado: (2014)

Downregulation of CD73 associates with T cell exhaustion in AML patients
por: Kong, Yaxian, et al.
Publicado: (2019)

CD70 CAR T cells in AML: Form follows function
por: Mirazee, Justin, et al.
Publicado: (2022)

Frequencies of CD33+CD11b+HLA-DR–CD14–CD66b+ and CD33+CD11b+HLA-DR–CD14+CD66b– Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19
por: Alberca, Ricardo Wesley, et al.
Publicado: (2020)

330 grabados originales
por: Manilla, Manuel
Publicado: (1971)

CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma
por: Lei, Wen, et al.
Publicado: (2022)

Broad-Snouted Caiman (Caiman latirostris) bite
por: Tarlé, Roberto Gomes, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_02v16siq9k87ungt8lgl2tj868